fda approved semaglutide New Weight Loss Medication Wegovy™ by the FDA approves pill version of
Description
Our specialists evaluate whether Mounjaros dual receptor action or Zepbounds targeted GLP-1 therapy is better suited to your weight loss goals

Phase 2 trial data (NEJM 2023) showed approximately 17.5% mean body weight reduction at 24 weeks at the highest dose, but week-4 figures were not reported as a primary endpoint
Semaglutide is a large peptide molecule that the body naturally breaks down before it can be absorbed through oral tissues

In both the phase 2 obesity trial and the MASLD substudy, no specific diet was prescribed and participants received generic lifestyle counseling rather than any carbohydrate-based protocol, yet significant weight loss and substantial liver fat reduction still occurred

10.1016/j.jep.2020.113052 [DOI] [PubMed] [Google Scholar] 36.Li N, Sun W, Zhou X, Gong H, Chen Y, Chen D, Xiang F
